What the FDA Just Reviewed About Seven Peptides
On July 23 and 24, 2026, an FDA advisory committee reviewed seven peptides for the 503A compounding list. Here is what was on the agenda and what it means.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met at the agency's White Oak campus to review seven peptides. The question in front of the committee was narrow but consequential: should these substances be added to a list that determines whether a compounding pharmacy can legally prepare them.
If you take one of these peptides, or you have been reading about them, this is the process that decides their future. It is worth understanding what was actually on the table, because a lot of what gets written about it online overstates both the good news and the bad.
What the 503A Bulks List actually is
Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions under which a licensed pharmacist can compound a drug for an individual patient without that product going through the full new drug approval process.
One of those conditions concerns the raw ingredient, the bulk drug substance. To qualify, the substance has to meet one of three tests. It complies with a United States Pharmacopeia or National Formulary monograph, if one exists. Or it is a component of a drug already approved by the FDA. Or, if neither of those applies, it appears on a list the agency develops by regulation, known as the 503A Bulks List.
Most peptides fail the first two tests. They have no USP monograph and they are not components of approved drugs. That leaves the third door, and the advisory committee's job is to advise FDA on who walks through it.
Being reviewed is not the same as being approved, and it is not the same as being banned. It is a step in a process that is still open.
Which peptides were on the agenda
The Federal Register notice for the meeting lists each substance and the specific use FDA evaluated it for. That second part matters, and we come back to it below.
On July 23, the committee took up four:
- BPC-157, free base and acetate, evaluated for ulcerative colitis
- KPV, free base and acetate, evaluated for wound healing and inflammatory conditions
- TB-500, free base and acetate, evaluated for wound healing
- MOTs-C, free base and acetate, evaluated for obesity and osteoporosis
On July 24, three more:
- Emideltide, also called delta sleep inducing peptide or DSIP, evaluated for opioid withdrawal, chronic insomnia, and narcolepsy
- Semax, free base and acetate, evaluated for cerebral ischemia, migraine, and trigeminal neuralgia
- Epitalon, free base and acetate, evaluated for insomnia
What "uses evaluated" means, and what it does not
This is the part most easily misread. The use listed beside each peptide is the indication FDA reviewed the nomination against. It is the frame for the analysis, not a finding that the substance works for that condition, and certainly not an endorsement.
So the notice listing BPC-157 next to ulcerative colitis does not mean FDA has concluded BPC-157 treats ulcerative colitis. It means someone nominated it for that use and the agency evaluated the nomination on those terms.
It is also worth noting how narrow some of these framings are compared to how the same peptides get marketed. BPC-157 is widely discussed online for tendon and joint recovery. The nomination FDA evaluated was about ulcerative colitis.
What happens next
The advisory committee advises. It does not decide. FDA takes the committee's input, along with public comment, and makes its own determination about whether a substance goes on the list.
The public docket for this meeting, numbered FDA-2025-N-6895, closed on July 22, 2026, the day before the meeting began. Comments submitted on or before July 9 were provided directly to the committee.
There is no published deadline by which FDA must act after an advisory committee meeting. The honest answer about timing is that nobody outside the agency knows.
What this means if you are a patient
A few things are true at the same time, and holding all of them is the accurate position.
These peptides are not FDA approved. None of them has been evaluated by FDA for safety and effectiveness the way an approved drug is. Their regulatory status for compounding is unsettled and is actively being worked out, which is exactly what this meeting was.
If you are currently on a protocol that includes one of these, the useful move is not to read a blog and react. It is to talk with the provider who prescribed it, who can tell you what your options look like specifically.
We will keep following this. When FDA acts, we will write about what it actually did, and link the primary document so you can read it yourself.
Common questions
Does this mean BPC-157 is banned?
No. The committee reviewed whether BPC-157 should be added to the 503A Bulks List, which is a list that permits compounding. A review is not a ban, and no final determination was announced at the meeting itself. FDA makes the decision after considering the committee's advice.
Is BPC-157 FDA approved?
No. None of the seven peptides reviewed is an FDA approved drug. They have not been evaluated by FDA for safety and effectiveness in the way approved medications are. That is precisely why the compounding question exists.
When will the FDA make a decision?
There is no published deadline. An advisory committee makes a recommendation, and FDA then decides on its own timeline. Anyone claiming to know the date is guessing.
Where can I read the source myself?
The Federal Register notice for the meeting is public and linked in the sources below. It names every substance, the use FDA evaluated, the meeting dates, and the docket number. It is the primary document, and it is short.
Sources
- 1.Pharmacy Compounding Advisory Committee; Notice of Meeting; Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List (Docket FDA-2025-N-6895) — Federal Register, FDA, 2026
- 2.Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — U.S. Food and Drug Administration, 2026
